1. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy
- Author
-
Hervé Tilly, Hélène Lanic, Romain Modzelewski, Florian Clatot, Jean Michel Picquenot, Sylvain Mareschal, Jerôme Kraut-Tauzia, Fabrice Jardin, Aspasia Stamatoullas, Stéphane Leprêtre, Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Breton, Céline, Service d'Oncologie Médicale, CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), service d'anatomo-pathologie, CRLCC Henri Becquerel, Equipe Quantification en Imagerie Fonctionnelle ( QuantIF-LITIS ), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes ( LITIS ), Université Le Havre Normandie ( ULH ), Normandie Université ( NU ) -Normandie Université ( NU ) -Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Institut national des sciences appliquées Rouen Normandie ( INSA Rouen Normandie ), Normandie Université ( NU ) -Université Le Havre Normandie ( ULH ), Normandie Université ( NU ), Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and CRLCC Haute Normandie-CRLCC Henri Becquerel
- Subjects
Male ,Sarcopenia ,MESH : Retrospective Studies ,MESH : Antineoplastic Combined Chemotherapy Protocols ,Body Surface Area ,MESH : Aged ,Gastroenterology ,Body Mass Index ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,MESH : Muscle, Skeletal ,MESH: Sarcopenia ,ComputingMilieux_MISCELLANEOUS ,MESH: Treatment Outcome ,Aged, 80 and over ,0303 health sciences ,education.field_of_study ,Prognosis ,3. Good health ,[SDV] Life Sciences [q-bio] ,MESH: Antineoplastic Combined Chemotherapy Protocols ,Oncology ,Vincristine ,030220 oncology & carcinogenesis ,Rituximab ,MESH : Vincristine ,medicine.medical_specialty ,Tomography Scanners, X-Ray Computed ,MESH : Tomography Scanners, X-Ray Computed ,MESH: Prognosis ,MESH: Body Mass Index ,MESH: Doxorubicin ,03 medical and health sciences ,Humans ,MESH : Aged, 80 and over ,education ,Cyclophosphamide ,Aged ,Retrospective Studies ,MESH: Age Factors ,MESH: Humans ,[ SDV ] Life Sciences [q-bio] ,MESH : Humans ,MESH : Prednisone ,MESH: Cyclophosphamide ,MESH: Retrospective Studies ,MESH : Organ Size ,medicine.disease ,MESH : Body Mass Index ,MESH : Sarcopenia ,MESH: Antibodies, Monoclonal, Murine-Derived ,MESH: Prednisone ,MESH: Female ,Body mass index ,Diffuse large B-cell lymphoma ,Cancer Research ,MESH: Organ Size ,[SDV]Life Sciences [q-bio] ,MESH : Lymphoma, Large B-Cell, Diffuse ,Antibodies, Monoclonal, Murine-Derived ,MESH: Aged, 80 and over ,MESH: Body Surface Area ,International Prognostic Index ,Prednisone ,hemic and lymphatic diseases ,MESH : Female ,MESH : Cyclophosphamide ,MESH: Aged ,Body surface area ,MESH: Muscle, Skeletal ,MESH : Prognosis ,Age Factors ,Hematology ,Organ Size ,Treatment Outcome ,Female ,Lymphoma, Large B-Cell, Diffuse ,medicine.drug ,MESH : Body Surface Area ,MESH : Male ,Population ,MESH: Vincristine ,MESH : Treatment Outcome ,Internal medicine ,medicine ,MESH : Doxorubicin ,Muscle, Skeletal ,030304 developmental biology ,MESH: Tomography Scanners, X-Ray Computed ,business.industry ,MESH: Male ,MESH : Antibodies, Monoclonal, Murine-Derived ,Surgery ,Doxorubicin ,MESH: Lymphoma, Large B-Cell, Diffuse ,MESH : Age Factors ,business - Abstract
International audience; Approximately 25-35% of patients with diffuse large B-cell lymphoma (DLBCL) are older than 70 years. The aim of this study was to investigate the prognostic impact of depletion of skeletal muscle (sarcopenia) in elderly patients with DLBCL. This retrospective analysis included 82 patients with DLBCL older than 70 years and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin, prednisone) or R-miniCHOP. Sarcopenia was measured by the analysis of stored computed tomography (CT) images at the L3 level at baseline. The surface of the muscular tissues was selected according to the CT Hounsfield unit. This value was normalized for stature in order to calculate the lumbar L3 skeletal muscle index (LSMI, in cm(2)/m(2)). The mean age of the population was 78 years. According to the defined cut-offs for LSMI, 45 patients with DLBCL were considered sarcopenic. Sarcopenic patients displayed a higher revised International Prognostic Index (R-IPI) compared with patients without sarcopenia, and were older, with a mean age of 80 years and 77 years, respectively (p = 0.006). With a median follow-up of 39 months, the 2-year overall survival in the sarcopenic population was 46% compared with 84% in the non-sarcopenic group (HR = 3.22; 95% CI = 1.73-5.98; p = 0.0002). In a multivariate analysis, sarcopenia remained predictive of outcome (p = 0.005). Sarcopenia is a relevant and predictive factor in elderly patients with DLBCL treated with rituximab plus chemotherapy.
- Published
- 2013